Top 5 Small Cap Stocks To Watch For 2018


The Q4 2017 earnings report for small cap high-definition video solutions stockAmbarella Inc (NASDAQ: AMBA) is scheduled for after the market closes onTuesday (February 28th).Ambarella Inc was in our SmallCap Network Elite Opportunity (SCN EO) portfolio when thecompany was offering attractive valuation metrics with good forward growth potential, but ourSCN EO hasalso suggested the stock as ashort trade:

Ambarella, Inc. (AMBA) has been all over the map over the last few years. It has defied gravity both to the up and to the downside, and although today’s suggested short of the stock is strictly technical, we do believe its current share price has once again gotten a little out of line when you compare it to the rest of the markets’ valuation metrics right now.

Top 5 Small Cap Stocks To Watch For 2018: Panera Bread Company(PNRA)


Advisors’ Opinion:

  • [By Ben Levisohn]

    Keurigs plight (actually, JABs) is worsening, with the K-cup market slowing to almost no growth now, and Keurig continuing to lose own brands share. Starbucks (SBUX) echoed the notion of a K-cup market slowdown at its seminar on Wednesday (and is guiding for its [consumer packaged goods, or CPG,] growth below recent trends), but it expects to increase its share of total CPG coffee to 20% from 15%. Come early February it will be a year since the closing of the Keurig deal for JAB Holdings. The pressure on JAB is more significant if we take into account the high leverage of the deal (JAB contributed one fourth of the $12Bn price tag). It is a tough predicament. On the one hand we argue that to make that deal work, they need to buy more (own) brands either from the retail channel (that can be extended to CPG: Dunkin (DNKN)? Panera (PNRA)?), or outright buy CPG brands (like the entire Kraft Heinz portfolio, and or Tata Groups Eight OClock brand). But can/how do they fund these deals? Maybe Mars and Warren Buffett (Mars is involved in office coffee with Starbucks), private equity, and or 3G can help? While this note is not about Positive-rated Mondelez, we have mentioned before a scenario where Kraft Heinz buys Mondelez and partly funds the deal by selling its own CPG coffee business (~$3Bn we say) to JAB as well as divests the Mondelez 20% plus stakes in Keurig (North America) and Jacobs Douwe Egberts (Western Europe), which together at this stage are worth ~$7-8Bn. But, yes, JAB will need deep-pocket partners and generous lenders. Net, JAB needs to do something soon.

  • [By WWW.THESTREET.COM]

    Then there’s Panera Bread (PNRA) , a company that had lost its way. But after interviewing Panera’s CEO Ron Shaich, Cramer learned that at its new, remodeled “Panera 2.0” stores, the lines were out the door. As the rollout continued, earnings only got stronger. Never underestimate the power of a restaurant redo, Cramer concluded.

  • [By WWW.THESTREET.COM]

    Cramer wanted to talk a little psychology. With its after-hours move Tuesday, Panera Bread (PNRA) is up more than 16% this week on takeover speculation. Panera is an old Action Alerts PLUS name, one the trust sold at a nice gain, too. 

  • [By Lisa Levin]

    Shares of Panera Bread Co (NASDAQ: PNRA) got a boost, shooting up 14 percent to $312.29 after the company agreed to be acquired by JAB for $7.5 billion.

Top 5 Small Cap Stocks To Watch For 2018: Rackspace Hosting Inc(RAX)

Advisors’ Opinion:

  • [By Monica Gerson]

    Rackspace Hosting, Inc. (NYSE: RAX) reported better-than-expected earnings for the first quarter, but the company missed analysts’ sales estimates. Rackspace shares dropped 7.72 percent to $20.80 in the after-hours trading session.

Top 5 Small Cap Stocks To Watch For 2018: FuelCell Energy Inc.(FCEL)


Advisors’ Opinion:

  • [By Paul Ausick]

    The North American subsidiary of Toyota Motor Corp. (NYSE: TM) is teaming up with alternative energy supplier Fuel Cell Energy Inc. (NASDAQ: FCEL) to build a fuel cell power generation unit and hydrogen fueling station at Toyota’s facilities at the Port of Long Beach, California. The new plant, which is forecast to come online in 2020, was unveiled Friday at the Los Angeles Auto Show.

  • [By Peter Graham]

    The Q1 2017 earnings report for small cap fuel cell stockFuelCell Energy Inc (NASDAQ: FCEL) is scheduled forbefore the marketopens onThursday (March 9th). Last December,FuelCell Energy announced a business restructuring to reduce costs and align production levels with current levels of demand in a manner that is consistent with the Companys long-term strategic plan.The Company said it cut 96 jobs, or 17% of its workforce, and has halved production to 25 megawatts a year in order to position for delays in order flow.

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap fuel cell stockFuelCell Energy Inc (NASDAQ: FCEL) is scheduled forbefore the marketopens onThursday (January 12th). At the beginning of December, FuelCell Energy announced a business restructuring to reduce costs and align production levels with current levels of demand in a manner that is consistent with the Companys long-term strategic plan.The Company said it cut 96 jobs, or 17% of its workforce, and has halved production to 25 megawatts a year in order to position for delays in order flow.The Company alsoexpects to take a $3 million charge in fiscal 2017 related to the job cuts.

Top 5 Small Cap Stocks To Watch For 2018: Achillion Pharmaceuticals Inc.(ACHN)


Advisors’ Opinion:

  • [By Paul Ausick]

    Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) dropped about 6.9% Friday to post a new 52-week low of $2.69 after closing at $2.89 on Thursday. The 52-week high is $5.66. Volume was around 6.2 million, more than three times the daily average of around 1.9 million. The company had no specific news.

  • [By Ben Levisohn]

    We updated our annual U.S. Hep C survey in early July, in order to gauge the future for Gilead, AbbVie/Enanta Pharmaceuticals (ENTA), Merck, and J&J/Achillion Pharmaceuticals (ACHN). In conjunction with script trends, physicians indicate that the market for treatment-eligible, easily accessible Hep C patients is shrinking, but that Gilead’s share of the shrinking pie is continuing to grow. With no end to script declines in sight, we are left wondering where the Hep C will bottom…